Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic…
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference Call Today to Discuss Findings at 4:30 p.m. Eastern Time SAN DIEGO,…